Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 7/20 | 0.37 |
| ▸ | ITK | Q08881 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808531 | 0.85 | REN (0.37) | SLC22A12RENKDM4EALDH1A1HPGD | |
| SCHEMBL2833989 | 0.81 | HRH1 (0.37) | SLC22A12RENKDM4EALDH1A1HPGD | |
| SCHEMBL2813578 | 0.81 | REN (0.44) | SLC22A12RENITK | |
| SCHEMBL2810347 | 0.81 | KDM4C (0.40) | RENITKKDM4EALDH1A1HPGD | |
| SCHEMBL2806953 | 0.80 | REN (0.33) | RENKCNH2HTR4 | |
| SCHEMBL13132446 | 0.78 | ITK (0.42) | SLC22A12RENITKKDM4EALDH1A1 | |
| SCHEMBL13132302 | 0.74 | REN (0.40) | SLC22A12RENITK | |
| SCHEMBL2840438 | 0.74 | REN (0.37) | RENKDM4EALDH1A1KCNH2HTR4 | |
| SCHEMBL2806190 | 0.73 | REN (0.45) | RENKCNH2HTR4 | |
| SCHEMBL13132439 | 0.73 | ITK (0.40) | SLC22A12RENITKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | SLC22A12 2804/4885REN 1/4885ITK 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.